STOCK TITAN

NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

Welcome to our dedicated page for NRX Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals stock.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage, small-molecule pharmaceutical company dedicated to developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company's flagship products include ZYESAMI (Aviptadil), aimed at treating COVID-related respiratory failure, and NRX-100/101, the first sequential drug regimen specifically designed for bipolar depression in patients with acute suicidal ideation and behavior.

Recently, NRX Pharmaceuticals announced a public offering of its common stock to raise funds for working capital, general corporate purposes, and to repay certain debts. The proceeds will also support the initiation of a national treatment protocol and a safety database.

Among its most notable developments, the company is advancing NRX-101, designated as an FDA Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX Pharmaceuticals has strategic partnerships with Alvogen and Lotus for the development and marketing of NRX-101.

The company also oversees Hope Therapeutics, focusing on the development and marketing of IV ketamine for the acute treatment of suicidality and depression, leveraging a digital therapeutic-enabled platform to augment clinical benefits.

NRX Pharmaceuticals' robust pipeline includes plans for a New Drug Application for HTX-100 (IV ketamine) based on promising clinical trial results. It has also received Fast Track Designation from the FDA for the development of ketamine as part of its treatment protocol for acute suicidality.

Furthermore, NRX Pharmaceuticals is exploring the use of NRX-101 for chronic pain and complicated UTI, marking its potential to address significant unmet medical needs across various therapeutic areas. The company remains committed to improving patient outcomes and advancing its innovative therapies through rigorous clinical trials and strategic collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.7%
Tags
covid-19
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.21%
Tags
none
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.99%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none

FAQ

What is the current stock price of NRX Pharmaceuticals (NRXP)?

The current stock price of NRX Pharmaceuticals (NRXP) is $1.63 as of September 6, 2024.

What is the market cap of NRX Pharmaceuticals (NRXP)?

The market cap of NRX Pharmaceuticals (NRXP) is approximately 17.8M.

What is NRX Pharmaceuticals' primary focus?

NRX Pharmaceuticals focuses on developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases.

What are NRX Pharmaceuticals' key products?

The key products include ZYESAMI (Aviptadil) for COVID-related respiratory failure and NRX-100/101 for bipolar depression with acute suicidal ideation.

What is the significance of NRX-101?

NRX-101 is an FDA-designated Breakthrough Therapy aimed at treating suicidal treatment-resistant bipolar depression and chronic pain.

Who are NRX Pharmaceuticals' strategic partners?

NRX Pharmaceuticals has partnered with Alvogen and Lotus for the development and marketing of NRX-101.

What recent developments has NRX Pharmaceuticals announced?

The company has announced a public offering to raise funds for working capital, initiating a national treatment protocol, and repaying debts.

What is Hope Therapeutics?

Hope Therapeutics is a subsidiary of NRX Pharmaceuticals, focusing on the development and marketing of FDA-approved intravenous ketamine for acute suicidality and depression.

What is the purpose of the public offering announced by NRX Pharmaceuticals?

The public offering aims to raise funds for working capital, general corporate purposes, and to repay certain outstanding debts.

What are the future plans for NRX-101?

NRX Pharmaceuticals plans to expand NRX-101’s use for chronic pain and complicated UTI, and potentially submit a New Drug Application based on clinical trial results.

Has NRX Pharmaceuticals received any special designations from the FDA?

Yes, NRX Pharmaceuticals has received Fast Track Designation from the FDA for the development of ketamine (NRX-100) as part of its treatment protocol for acute suicidality.

What is the financial condition of NRX Pharmaceuticals as of the latest update?

As of the latest update, NRX Pharmaceuticals is in the process of raising funds through a public offering and has received $5 million from a milestone payment, improving its working capital situation.

NRX Pharmaceuticals, Inc.

Nasdaq:NRXP

NRXP Rankings

NRXP Stock Data

17.76M
10.75M
26.2%
4.71%
3.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON